权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Targeting GRP94-TGF-beta Pathway for Cancer Immunotherapy Supplement

靶向 GRP94-TGF-β 通路的癌症免疫治疗补充剂

基本信息

批准号：
10818173
负责人：
Zihai Li
金额：
$ 7.21万
依托单位：
OHIO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-01 至 2026-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10818173
关键词：
Address Antibodies Area B-Lymphocytes Binding Biochemical Biogenesis Biology Blood Platelets Cancer Biology Cancer Control Cell surface Client Clinical Clinical Trials Collaborations Complex Degradation Pathway Development Docking Endoplasmic Reticulum Eragrostis Foundations GRP94 Goals Growth Factor Receptors Heat-Shock Proteins 90 Human Immune Immune Tolerance Immune checkpoint inhibitor Immunity Immunologics Immunotherapeutic agent Immunotherapy Insulin-Like Growth Factor I Insulin-Like Growth Factor II Integrins LRRC32 gene Laboratories Malignant Neoplasms Manuscripts Mediating Membrane Glycoproteins Molecular Molecular Chaperones Myelogenous Nature Oncogenic PD-1/PD-L1 Pathway interactions Pharmaceutical Preparations Phase Play Pre-Clinical Model Proteins Publishing Quality Control Regulation Regulatory T-Lymphocyte Renaissance Resistance Role Signal Pathway Signal Transduction Structural Biologist Suppressor-Effector T-Lymphocytes Surface T cell therapy T-Lymphocyte Therapeutic Thrombin Transforming Growth Factor beta Translational Research Tumor Escape VWF gene anti-cancer cancer cell cancer immunotherapeutics cancer immunotherapy cancer therapy cell growth cell type chimeric antigen receptor convict design effector T cell engineered T cells genetic approach immune checkpoint immune resistance inhibitor insight leucine-rich repeat protein migration new therapeutic target next generation novel novel therapeutics overexpression paralogous gene pre-clinical preclinical study protein degradation receptor response side effect targeted treatment tumor microenvironment tumorigenesis

项目摘要

PROJECT SUMMARY As a ubiquitous HSP90 paralog in the endoplasmic reticulum (ER), GRP94 plays important roles in protein quality control in the secretory pathway by participating in both the unfolded protein response and the ER-associated protein degradation pathway. My laboratory has demonstrated that GRP94 is a strategically important target for cancer, because it controls multiple key molecular pathways in cell growth, migration, immune tolerance and differentiation, including integrins, TLRs, IGF-II, Wnt co-receptor LRP6, and GARP (or LRRC32). GARP (Glycoprotein A Repetitions Predominant) is responsible for surface docking and activation of latent TGFb and a focus of this proposal We have made significant contributions to this area through immunological and biochemical studies, including: 1) that GARP is an important molecule for cancer immune evasion via regulating multiple cell types (e.g., cancer cells, platelets, regulatory T cells, B cells). 2) We discovered a novel mechanism of TGFb activation from cell surface GARP-TGFb complex via proteolytic cleavage of GARP. 3) GARP has been found to be aberrantly expressed in multiple human cancers to promote oncogenesis via both cancer cell-intrinsic and -extrinsic mechanisms. 4) Preclinical studies suggest that GARP is a novel therapeutic target for cancer immunotherapy. These accomplishments have deepened our conviction that the study of GRP94 and its client network will lead to better understanding of this chaperone biology in cancer and to development of novel cancer therapeutics, alone or in combination with approved immunotherapeutic agents. In the next phase of the study, we will address the hypothesis that GRP94/GARP-targeted therapy applied to multiple vulnerable cancers will overcome immune resistance to checkpoint inhibitors. First, we will determine the roles and molecular mechanism involved in GRP94 regulation of TGFb biogenesis, activation and signaling. This aim will focus on structural analysis of the GRP94-GARP complex, and on resolving mechanisms of GRP94 in folding two other molecules important in regulating TGFb signaling: LRRC33 and LRG1. Second, we will develop novel cancer immunotherapeutic strategies targeting GRP94 and GARP. The goal is to advance the top first-in-class agent(s) among several pre-clinical leads through a milestone-driven strategy. This includes agents to inhibit GARP cleavage, GARP-specific antibodies, drug-like GRP94-selective inhibitors, antibodies against the cell surface GRP94 (ectoGRP94) preferentially expressed on cancer cells, and T cells engineered to express chimeric antigen receptor (CAR) composed of a single-chain antibody against ectoGRP94 fused with T cell signaling motifs (GRP94-CAR-T). Overall, the impact of this study lies in fundamental understanding of GRP94 in regulating the TGFb pathway and in developing promising next generation immunotherapeutic agents.

项目总结